<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210041</url>
  </required_header>
  <id_info>
    <org_study_id>03 GENH 06</org_study_id>
    <secondary_id>02 GENM 02</secondary_id>
    <nct_id>NCT00210041</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma</brief_title>
  <official_title>Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether association Gemcitabine-Cisplatin is
      effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or
      metastatic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate objective response rate</measure>
    <time_frame>until desease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate tolerance of the association,</measure>
    <time_frame>during all participation of the subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression,</measure>
    <time_frame>untill progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global survival</measure>
    <time_frame>untill death</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Genital Neoplasms, Male</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  OMS ≤ 2

          -  Penis epidermoid carcinoma histologically proved. Tumor with ganglionic loco-regional
             injury inextirpable and/or metastatic (M1, all T , all N), at initial diagnostic or at
             relapse after first treatment with curative aim (surgery and / or radiotherapy)

          -  Disease measurable with RECIST criteria

          -  Absence of all former chemotherapy during 5 years between inclusion.

          -  If former radiotherapy, necessity to have appreciated targets outside the irradiation
             fields. If former radiotherapy, it must have been done more than 4 weeks before
             inclusion in the study.

          -  Biologicals values required : polynuclear neutrophils ≥ 1500/mm3, blood-platelets ≥
             100000/mm3, Hb ≥ 10 g/dl, Transaminases &lt; 3N, TP ≥ 70%, total bilirubin &lt; 1,5 N,
             creatinine in the blood ≤ 110 micromoles/l.

          -  Normal clearance of creatinine, according to Cockroft and Gault's formulae.

          -  Calcemia : normal or anomaly without clinical meaning.

          -  Well-informed written consent, signed by the patient.

        Exclusion Criteria:

          -  Uncontrolled cerebral known metastasis

          -  All former chemotherapy administration during 5 years between inclusion

          -  Other cancer (except baso-cellular cancer of skin correctly treated, or cancerous
             disease considered with good prognosis and on remission until 5 years at least)

          -  Uncontrolled cardiac insufficiency or all other severe and uncontrolled pathology.

          -  Peripheric neuropathy ≥ grade 2 OMS

          -  Anormal audiogram

          -  Patient difficult to follow for geographical, psychological or family reasons.

          -  Persons protected by law.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Chevreau, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Val d'aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Médico-Chirurgical Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genital Neoplasms, Male</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Male</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

